Fulcrum Therapeutics, Inc.

NasdaqGM:FULC Stok Raporu

Piyasa değeri: US$200.3m

Fulcrum Therapeutics Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Fulcrum Therapeutics'in gelir ve kazançlarının sırasıyla 80% ve 21.5% yıllık düşüş göstermesi beklenirken, EPS'nin 19.3% azalması beklenmektedir.

Anahtar bilgiler

-21.5%

Kazanç büyüme oranı

-19.3%

EPS büyüme oranı

Pharmaceuticals kazanç büyümesi23.6%
Gelir büyüme oranı-80.0%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Good

Son güncelleme04 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Sep 13
Some Confidence Is Lacking In Fulcrum Therapeutics, Inc. (NASDAQ:FULC) As Shares Slide 62%

Fulcrum Therapeutics: Tough Day As Losmapimod FSHD Phase 3 Misses Badly

Sep 12

Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Jul 12
Will Fulcrum Therapeutics (NASDAQ:FULC) Spend Its Cash Wisely?

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Feb 11
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Oct 28
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

Jul 11
We Think Fulcrum Therapeutics (NASDAQ:FULC) Needs To Drive Business Growth Carefully

What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

Nov 17
What You Need To Know About The Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analyst Downgrade Today

We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Oct 18
We're Keeping An Eye On Fulcrum Therapeutics' (NASDAQ:FULC) Cash Burn Rate

Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13
Newsflash: Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Analysts Have Been Trimming Their Revenue Forecasts

Fulcrum Therapeutics GAAP EPS of -$0.83 misses by $0.17, revenue of $1.9M misses by $1.06M

Aug 11

Fulcrum Therapeutics says chief medical officer Christopher Morabito to leave

Jul 11

Fulcrum begins dosing in late-stage study of losmapimod for rare muscle disorder

Jul 05

Fulcrum Therapeutics: Value Loss On SCD Data Update Is Telling

Jun 27

These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

May 10
These Analysts Think Fulcrum Therapeutics, Inc.'s (NASDAQ:FULC) Sales Are Under Threat

Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Apr 09
Companies Like Fulcrum Therapeutics (NASDAQ:FULC) Are In A Position To Invest In Growth

Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Dec 09
Fulcrum Therapeutics (NASDAQ:FULC) Is In A Good Position To Deliver On Growth Plans

Fulcrum Therapeutics: Multiple Interesting Programs, Needs A Better Entry Point

Sep 03

Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

Aug 12
Analysts Are Upgrading Fulcrum Therapeutics, Inc. (NASDAQ:FULC) After Its Latest Results

News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Aug 11
News Flash: Analysts Just Made A Meaningful Upgrade To Their Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Forecasts

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:FULC - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
12/31/2026N/A-55-50-575
12/31/2025N/A-62-46-506
12/31/202480-14-12-57
6/30/202482-20-13-12N/A
3/31/20243-99-92-92N/A
12/31/20233-97-91-91N/A
9/30/20233-99-88-88N/A
6/30/20233-98-93-92N/A
3/31/20234-109-101-99N/A
12/31/20226-110-99-97N/A
9/30/202211-107-102-99N/A
6/30/202214-104-96-94N/A
3/31/202217-90-86-84N/A
12/31/202119-81-80-78N/A
9/30/202118-75-78-76N/A
6/30/202115-73-60-58N/A
3/31/202113-69-56-55N/A
12/31/20209-71-55-54N/A
9/30/20205-69-39-38N/A
6/30/20203-68-48-47N/A
3/31/20201-68-46-45N/A
12/31/2019N/A-90-40-39N/A
9/30/2019N/A-85-46-41N/A
6/30/2019N/A-79-38-32N/A
3/31/2019N/A-71-34-26N/A
12/31/2018N/A-39-32-23N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: FULC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: FULC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: FULC önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: FULC şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi bekleniyor (yılda -80% ).

Yüksek Büyüme Geliri: FULC şirketinin gelirinin önümüzdeki 3 yıl içinde düşmesi öngörülüyor (yılda -80% ).


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: FULC 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin